Gastrointestinal study results produced healthy returns for a biotech stock Tuesday. Here’s some small stocks making big moves on Tuesday, March 20, 2018 (as of 4 pm EST):
Antibe Therapeutics Inc. (TSXV:ATE), a biotech stock, soared 78% to $0.64 on Tuesday after announcing that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal safety study.
As well, shares of Ballard Power Systems (TSX:BLDP) rose 10% to $4.59 as the clean energy products provider said it has signed a contract with CALSTART for a Ballard 30 kilowatt FCveloCity-MD fuel cell module to be used in a trial and development program involving UPS Class-6 delivery vans operating in California’s South Coast Air Basin, including much of the Greater Los Angeles area.
Cardiome Pharma Corp. (TSX:COM), meanwhile, reported that it will sell its Canadian business portfolio to Cipher Pharmaceuticals Inc. (TSX:CPH) for an upfront consideration of C$25.5 million. Cardiome Pharma stock popped 15% to $2.35 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Antibe Therapeutics Inc. (TSXV:ATE), a biotech stock, soared 78% to $0.64 on Tuesday after announcing that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal safety study.
